Total Value in 2013: $6,192M* Number of Deals in 2013: 97 Company (Location) Company (Location) Value (M) Type/Product Area Terms/Details Date APRIL Alchemia Ltd. (Brisbane, Australia) AstraZeneca AB (Sodertalje, Sweden; unit of AstraZeneca plc) $240 Deal for Alchemia's Diversity Scanning Array and Versatile Assembly on Stable Templates technologies to discover and develop small molecules for multiple targets in the oncology, respiratory, cardiovascular, metabolism, infection and neuroscience

Ltd., of Shanghai, which granted SciClone a license and exclusive rights in China, Hong Kong and Macau to promote, market, distribute and sell Neucardin in intermediate to advanced chronic heart failure...and three Phase IIb studies in China – showed that Neucardin improved cardiac function, reversed ventricular remodeling and increased the survival of heart failure patients

The study, which was carried out at Erasmus University Medical Center in Rotterdam, found that a single intracoronary MPC infusion decreased infarct size in sheep by 40 percent, abrogated left ventricular adverse remodeling, reduced left ventricular volumes, increased small and larger blood vessel density by 71 percent (capillaries) and 127 percent (arterioles), and prevented heart failure

Cardio3 BioSciences (C3BS) closed a €19 million (US$25 million) investment round to fund an ongoing European Phase III trial of its stem cell therapy for ischemic heart failure, C-Cure...Other firms with ongoing trials of stem cell therapies for chronic heart failure or chronic myocardial ischemia include Baxter International Inc., of Deerfield, Ill

While RAAS treatments have been shown to reduce deaths in patients with CKD and congestive heart failure, they can cause potassium retention, resulting in hyperkalemia and limiting their use...Patiromer has been shown to lower serum potassium and prevent hyperkalemia in patients with CKD or congestive heart failure with reduced kidney function, potentially giving prescribers more treatment options

heart failure Enrolled its first patients in a Phase IIb trial 4/5/13 Acorda Therapeutics Inc. (Ardsley, N.Y.) Ampyra Dalfampridine Stroke Improved walking in people with post-stroke deficits such as impaired walking, motor and sensory function, and manual dexterity in a proof-of-concept trial 4/16/13 GlycoMimetics Inc. (Gaithersburg, Md.) GMI-1070 A synthetic glycomimetic molecule Vaso-occlusive crisis of sickle cell disease Top-line Phase II data showed treated patients experienced reduction

Cardio3 BioSciences closed a $25 million investment round to fund an ongoing European Phase III trial of its stem cell therapy for ischemic heart failure

brings a $30 million equity investment in exchange for an option to license worldwide rights to TRV027, an angiotensin II Type I receptor (AT1R) biased ligand for acute decompensated heart failure (ADHF), after results are clear from a 500-patient Phase IIb trial, slated to begin by the end of the year...To put it in layman's terms, the technology enables us to really separate the good signaling from the signaling you don't want at the receptor, so it's much more specific, and a completely new

In diastolic heart failure, the heart is still able to pump, but the thickening of the heart muscle means that its pumping volume is reduced, which ultimately leads to blood backing up in the lungs...While there are treatments for some types of heart failure, none of them work in elderly patients with diastolic heart failure, which affects about 1 percent of those who are older than 50

Cardio3 BioSciences (C3BS) closed a €19 million ($25 million) investment round to fund an ongoing European Phase III trial of its stem cell therapy for ischemic heart failure, C-Cure...Other firms with ongoing trials of stem cell therapies for chronic heart failure or chronic myocardial ischemia include Baxter International Inc., of Deerfield, Ill

Both involve Ambrx's protein medicinal chemistry technology, one targeting fibroblast growth factor 21 for Type II diabetes and the other focused on the relaxin hormone for the treatment of heart failure

Total Value in 2013: $5,960.77M* Number of Deals in 2013: 93 Company (Location) Company (Location) Value (M) Type/Product Area Terms/Details Date FEBRUARY Ablynx NV (Ghent, Belgium) Spirogen Ltd. (London) ND Research collaboration to evaluate the potential of a cancer drug conjugate combining Spirogen's cytotoxic drugs, pyrrolobenzodiazepines and associated linker technology, with Nanobodies generated Ablynx will provide access to Nanobodies against an undisclosed target, and Spirogen will

ARCA biopharma Inc., of Broomfield, Colo., entered an agreement with Medtronic Inc., of Minneapolis, for a Phase IIb/III trial, GENETIC-AF, to compare lead drug Gencaro (bucindolol hydrochloride) to metoprolol CR/XL for prevention of atrial fibrillation in patients with heart failure and reduced left ventricular ejection fraction

Proceeds will be used to advance its gene therapy product for congestive heart failure into clinical development

In the prospective, randomized study, patients with chronic heart failure secondary to ischemic cardiomyopathy received treatment with their own stem cells engineered to become progenitors of cardiac cells...Based on those results, Cardio3 has begun a Phase III trial (CHART-1) in congestive heart failure

Merck Serono will donate an initial €2.8 million (US$3.7 million) and will transfer the rights of rimeporide, a compound previously developed for heart failure by Merck

Heart failure Phase I data showed a single dose was generally well tolerated up to 0.75 mg/kg, which higher doses might be associated with reversible hepatotoxic events 3/8/13 BioCryst Pharmaceuticals Inc. (Research Triangle Park, N.C.) BCX4161 A selective inhibitor of plasma kallikrein Hereditary angioedema Started a Phase I trial 3/27/13 Bioheart Inc. (Sunrise, Fla.) LipiCell Adipose-derived stem cells Congestive heart failure Beginning a Phase I trial 3/22/13 Catabasis Pharmaceuticals Inc

In the prospective, randomized study, patients with chronic heart failure secondary to ischemic cardiomyopathy received treatment with their own stem cells engineered to become progenitors of cardiac cells...The randomized, double-blind trial will enroll about 250 patients on stable, optimized, guideline heart failure therapy with symptoms of fluid overload to receive 15 g of CLP-1001 or placebo

Death eventually results from complications like pneumonia or heart failure